These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12525521)

  • 1. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
    Bodurka DC; Levenback C; Wolf JK; Gano J; Wharton JT; Kavanagh JJ; Gershenson DM
    J Clin Oncol; 2003 Jan; 21(2):291-7. PubMed ID: 12525521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
    Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
    Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
    J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
    Kim YM; Lee SW; Kim DY; Kim JH; Nam JH; Kim YT
    J Chemother; 2010 Jun; 22(3):197-200. PubMed ID: 20566426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
    Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
    Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.
    Choi MK; Ahn BJ; Yim DS; Park YS; Kim S; Sohn TS; Noh JH; Heo JS; Lee J; Park SH; Park JO; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):5-11. PubMed ID: 20213078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
    Kindler HL; Herndon JE; Zhang C; Green MR;
    Lung Cancer; 2005 Jun; 48(3):423-8. PubMed ID: 15893012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan in epithelial ovarian cancer.
    Gershenson DM
    Oncology (Williston Park); 2002 May; 16(5 Suppl 5):29-31. PubMed ID: 12109803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
    Lee M; Kim SW; Nam EJ; Cho H; Kim JH; Kim YT; Kim S
    Yonsei Med J; 2014 Nov; 55(6):1664-71. PubMed ID: 25323906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer.
    Matsumoto K; Katsumata N; Yamanaka Y; Yonemori K; Kohno T; Shimizu C; Andoh M; Fujiwara Y
    Gynecol Oncol; 2006 Feb; 100(2):412-6. PubMed ID: 16298422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
    Berkenblit A; Seiden MV; Matulonis UA; Penson RT; Krasner CN; Roche M; Mezzetti L; Atkinson T; Cannistra SA
    Gynecol Oncol; 2004 Dec; 95(3):624-31. PubMed ID: 15581974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
    Nomura H; Tsuda H; Kataoka F; Chiyoda T; Yamagami W; Tominaga E; Susumu N; Aoki D
    Eur J Gynaecol Oncol; 2012; 33(1):86-9. PubMed ID: 22439412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
    Hussain MM; Kotz H; Minasian L; Premkumar A; Sarosy G; Reed E; Zhai S; Steinberg SM; Raggio M; Oliver VK; Figg WD; Kohn EC
    J Clin Oncol; 2003 Dec; 21(23):4356-63. PubMed ID: 14645425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
    Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
    Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
    Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
    Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.